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Background
In the United States, Prostate cancer is the most com-
m o nt u m o u ri nm e n ,w i t ha ne x p e c t e d1 9 2 . 2 8 0n e w
cases and 27.360 deaths estimated in 2009 [1]. About
81% of patients with prostate cancer are over 65 years
of age. Prostate cancer is a biologically heterogeneous
neoplasm in which, especially in the elderly, some forms
remain silent and with risk of disease-treatment. More-
over, this population may not receive optimal therapies
for their disease, if decisions are based only on their
chronological age. Health status, more than age, is a
major factor affecting individual life expectancy. Comor-
bidity is the key predictor of health status, and should
weigh more on the treatment decision than age alone.
Other important parameters to consider in the elderly
are the degree of dependence in activities of daily living,
the nutritional status and the presence or not of a geria-
tric syndrome. The androgen-deprivation therapy (ADT)
has become an integral piece of the armamentarium for
treating prostate cancer in neoadjuvant, adjuvant and
palliative therapy [2]. The impact on health-related qual-
ity of life (HRQOL) following ADT induction has gained
significant clinical attention. Several series documented
an association between ADT and declining HRQOL [3].
Treatment of hormone refractory metastatic prostate
cancer with Docetaxel 75 mg/m
2 every 3 weeks (3W) in
combination with daily prednisone has been shown to
prolong survival and to have the same efficacy in healthy
elderly as in younger patients [4].
Conclusions
Geriatric assessment in elderly patients with prostate
cancer is crucial. Each treatment has to be adapted to
health status.
Published: 19 May 2010
References
1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer Statistics, 2009. Ca
Cancer J Clin 2009, 59:225-249.
2. Kumar S, Shelley M, Harrison C, Coles B, Wilt TJ, Mason MD: Neo-adjuvant
and adjuvant hormone therapy for localised and locally advanced
prostate cancer. Cochrane Database Syst Rev 2006, 18(4):CD006019.
3. Dacal K, Sereika SM, Greenspan SL: Quality of life in prostate cancer
patients taking androgen deprivation therapy. J Am Geriatr Soc 2006,
54:85-90.
4. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S,
Théodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA:
Docetaxel and prednisone or mitoxantrone plus prednisone for
advanced prostate cancer. N Engl J Med 2004, 351:1502-1512.
doi:10.1186/1471-2318-10-S1-L37
Cite this article as: Grillone: Tumours of the prostate. BMC Geriatrics 2010
10(Suppl 1):L37.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Medical Oncology Unit, Magna Graecia University and Tommaso Campanella
Cancer Center, Campus Salvatore Venuta, Catanzaro, Italy
Grillone BMC Geriatrics 2010, 10(Suppl 1):L37
http://www.biomedcentral.com/1471-2318/10/S1/L37
© 2010 Grillone; licensee BioMed Central Ltd.